Enveric Biosciences (ENVB) moves principal executive offices to Cambridge, MA

Rhea-AI Filing Summary

Enveric Biosciences, Inc. filed a current report to announce an operational change and related communication. Effective September 2, 2025, the company changed its principal executive office address to 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142. The company also furnished a press release as an exhibit, which discusses the same matters under Regulation FD. Enveric’s common stock, with a par value of $0.01 per share, continues to trade on The Nasdaq Stock Market under the symbol ENVB.

false 0000890821 0000890821 2025-09-02 2025-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 2, 2025

Date of Report (Date of earliest event reported)

Enveric Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38286		95-4484725
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Enveric Biosciences, Inc.

245 First Street, Riverview II, 18th Floor
Cambridge, MA, 02142

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (239) 302-1707

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		ENVB		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 2, 2025, Enveric Biosciences, Inc. (the “Company”) issued a press release announcing the matters disclosed in response to Item 8.01 below. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that is furnished pursuant to this Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

Effective September 2, 2025, the Company changed its address for its principal executive offices to 245 First Street, Riverview II, 18^th Floor, Cambridge, MA 02142.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release, dated September 2, 2025 (furnished pursuant to Item 7.01)
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 2, 2025	ENVERIC BIOSCIENCES, INC.
	By:	/s/ Joseph Tucker
		Joseph Tucker, Ph.D.
		Chief Executive Officer

FAQ

What did Enveric Biosciences (ENVB) report in this 8-K filing?

Enveric Biosciences reported an operational update, mainly a change in its principal executive office address effective September 2, 2025. The filing also notes that a related press release was furnished as an exhibit under Regulation FD Disclosure rules.

What is the new principal executive office address for Enveric Biosciences (ENVB)?

Enveric Biosciences’ new principal executive office address is 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142. This change became effective on September 2, 2025 and is the primary business location disclosed for the company.

When did Enveric Biosciences’ address change become effective?

The address change for Enveric Biosciences became effective on September 2, 2025. On that date, the company’s principal executive offices officially moved to 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142 as disclosed under Item 8.01.

What exhibits did Enveric Biosciences (ENVB) include with this 8-K?

Enveric Biosciences included two exhibits: Exhibit 99.1, a press release dated September 2, 2025 furnished under Item 7.01, and Exhibit 104, the cover page interactive data file formatted as Inline XBRL for reporting and data-tagging purposes.

On which exchange is Enveric Biosciences’ common stock listed and under what symbol?

Enveric Biosciences’ common stock, with a par value of $0.01 per share, is listed on The Nasdaq Stock Market. The trading symbol for the company’s common stock on that exchange is ENVB, as disclosed in the filing’s securities section.

Who signed the 8-K filing for Enveric Biosciences (ENVB)?

The 8-K filing was signed on behalf of Enveric Biosciences by Joseph Tucker, Ph.D. He signed in his capacity as Chief Executive Officer, indicating his authorization and responsibility for the information presented in the current report.